Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 5/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493765 | 0.90 | ALDH1A1 (0.63) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL494586 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL16099153 | 0.86 | KMT2A (0.53) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL6843065 | 0.83 | KMT2A (0.70) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL3771250 | 0.83 | CACNA2D1 (0.53) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL692922 | 0.82 | MAOB (0.71) | ALDH1A1NPSR1KDM4EKMT2AL3MBTL3 | |
| SCHEMBL3773398 | 0.82 | FASN (0.54) | ALDH1A1CNR1CNR2NPSR1KDM4E | |
| SCHEMBL493687 | 0.82 | L3MBTL1 (0.51) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL5136398 | 0.81 | KMT2A (0.52) | ALDH1A1CNR1CNR2NPSR1MAPT | |
| SCHEMBL3766753 | 0.81 | KMT2A (0.51) | ALDH1A1CNR1CNR2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | claimed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| CN-101316846-A | Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | CN | claimed |
| EP-1940845-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | claimed |
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| CN-101316846-A | Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | CN | disclosed |
| EP-1940845-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | ALDH1A1 3556/4885CNR1 359/4885CNR2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.